# Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)

> **NCT01745354** · PHASE1 · TERMINATED · sponsor: **Robert Lowsky** · enrollment: 6 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Hodgkin Disease

## Interventions

- **DRUG:** SD-101
- **RADIATION:** Local Radiation

## Key facts

- **NCT ID:** NCT01745354
- **Lead sponsor:** Robert Lowsky
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Accrual issues - Slow accrual
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01745354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01745354, "Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01745354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*